In a move that signals a seismic shift in the consolidation of American healthcare, HealthSpan Partners—the investment arm of the Catholic health giant Bon Secours—has announced its intention to take Surgery Partners private. This ambitious acquisition aims to absorb the latter’s expansive network of outpatient facilities, which currently spans 30 states. The deal, which reflects a broader trend of health systems aggressively pursuing ambulatory care footprints, represents one of the most significant efforts to date to internalize the delivery of high-acuity surgical care outside the traditional hospital setting.
By folding Surgery Partners into its organizational structure, Bon Secours is positioning itself to capture a larger share of the lucrative outpatient surgical market, focusing on high-margin procedures such as orthopedic, spinal, and cardiovascular care.
The Core Facts: A Strategic Integration
The proposed acquisition is not merely a financial transaction; it is a fundamental realignment of Bon Secours’ clinical strategy. Surgery Partners, a major player in the ambulatory surgery center (ASC) space, brings with it a sophisticated infrastructure that allows for complex procedures to be performed in lower-cost, more convenient environments.
HealthSpan Partners has confirmed that the acquisition will be financed through a combination of existing cash reserves and new debt issuance. Despite the transition to private ownership, Surgery Partners will retain its branding, corporate name, and its long-standing headquarters in Brentwood, Tennessee. Notably, the agreement stipulates that while Surgery Partners will continue to operate as a secular organization, it will align its clinical practices with the core Catholic-based values upheld by Bon Secours. This hybrid model attempts to balance the commercial agility of a private surgical group with the mission-driven approach of one of the nation’s largest non-profit health systems.
Chronology of Expansion: From PE Backing to Health System Ownership
The trajectory of Surgery Partners is a testament to the influence of private equity in modern medicine.
- 2010–2017 (The PE Era): For over a decade, Surgery Partners was a primary target for private equity growth strategies. H.I.G. Capital, a global investment firm, served as the primary architect of the company’s early expansion, scaling the business significantly before offloading its majority interest to Bain Capital in 2017.
- 2021–2024 (Rapid Scaling): Following the pandemic, the demand for outpatient surgical options skyrocketed. Surgery Partners responded by aggressively expanding its facility footprint, nearly doubling its operational centers in just three years. This period was marked by massive capital expenditure aimed at dominating regional markets.
- Late 2024–2025 (The Bon Secours Merger): The current acquisition phase signals the end of Surgery Partners’ life as a public-facing entity, transitioning it from a vehicle for private equity returns into a strategic asset for a mission-based health system.
Supporting Data: Why Outpatient is the Future
The decision to acquire Surgery Partners is backed by compelling economic and clinical data. As the healthcare landscape shifts, hospital margins have become increasingly thin, forcing systems to look toward outpatient services as the primary engine of financial sustainability.
The Shift to Lower-Cost Settings
Data suggests that outpatient services now account for the majority of hospital revenues across nearly all facility types in the United States. This shift is driven by a convergence of medical innovation and regulatory updates. Procedures that once required a three-day hospital stay—such as complex joint replacements and spinal fusions—are now routinely performed in outpatient settings.
- Market Growth: Surgery Partners reported a 22% increase in joint replacement volumes over the past year, highlighting the massive consumer preference for shorter, more convenient surgical encounters.
- Regulatory Tailwinds: CMS and commercial payers have actively incentivized this migration to ASCs, viewing them as a critical lever to control runaway healthcare inflation by eliminating the "hospital tax" associated with inpatient overhead, 24/7 nursing, and facility maintenance.
- The Profitability Gap: While Surgery Partners reported losses of $77.9 million last year—a common side effect of rapid expansion and heavy debt-servicing—the long-term valuation of their assets remains high. By absorbing these centers, Bon Secours is betting that the synergy of its primary care networks and the specialized surgical capacity of Surgery Partners will turn these losses into long-term margins.
Official Responses and Strategic Vision
The leadership at Bon Secours views this acquisition as a necessary evolution. John Starcher Jr., President and CEO of Bon Secours, emphasized the need for versatility in a changing market.
"As healthcare continues to evolve, it is important to grow in ways that allow us to serve more people, in more communities, and through a broader range of care settings," Starcher said in a recent press release.
For Bon Secours, this deal is about "meeting the patient where they are." By owning the entire continuum of care—from the initial consultation at a primary care clinic to the surgery at an ASC, and finally the rehabilitation—the system hopes to reduce leakage and improve clinical outcomes through standardized, integrated pathways.
Implications for the Industry
The acquisition of Surgery Partners carries significant implications for both patients and competitors.
1. The Consolidation Wave
Bon Secours is not alone in this strategy. The industry is witnessing a "land grab" for outpatient facilities. Earlier this summer, Ascension closed a $3.9 billion deal to acquire AmSurg, which operated over 250 ambulatory surgery centers. These massive deals indicate that standalone ASCs are becoming increasingly rare as they are gobbled up by regional and national health systems.
2. Clinical Standardization vs. Autonomy
A major question for the industry is how the "secular" nature of Surgery Partners will blend with the "Catholic-based" governance of Bon Secours. While the organizations have promised a smooth transition, the integration of clinical protocols—particularly concerning reproductive health, end-of-life care, and specific elective procedures—will be closely watched by industry analysts and patient advocacy groups.
3. Pricing and Competition
While the stated goal of these acquisitions is to lower costs by moving care to cheaper settings, critics often point to the potential for market monopolization. As systems like Bon Secours gain control over the majority of outpatient surgical capacity in a given region, they may gain significant leverage in contract negotiations with commercial insurers, which could ultimately lead to higher prices for employers and patients.
4. Financial Risk
The $77.9 million loss reported by Surgery Partners serves as a cautionary tale. While the model is highly scalable, it is also capital-intensive. Bon Secours is taking on substantial debt to finance this deal, placing immense pressure on the management team to quickly improve operational efficiency and integration to ensure that the debt load does not jeopardize the health system’s broader financial stability.
Conclusion: A New Era of Surgical Delivery
The proposed acquisition of Surgery Partners by HealthSpan/Bon Secours marks a definitive turning point. It signals that the "hospital-centric" era of the 20th century is being replaced by a "distributed" model of care. As surgical capacity moves out of the four walls of the traditional hospital, health systems that fail to secure their own outpatient networks risk losing market share to those that do.
For patients, the transition promises more convenient, potentially less expensive, and highly efficient surgical experiences. For the healthcare industry, however, the deal raises fundamental questions about the limits of consolidation, the importance of maintaining competition, and the challenge of integrating corporate scale with the delivery of compassionate, patient-centered care. As the regulatory and financial dust settles on this deal, it will likely serve as the blueprint—or a warning—for the next decade of healthcare evolution.
